The study about the effects of cholesterol absorption inhibition on coronary artery plaque in patients treated with PCI

The study about the effects of cholesterol absorption inhibition on coronary artery plaque in patients treated with PCI - The effects of ezetimibe on coronary plaque

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026581

Enrollment

Registered

2017-04-01

Start date

2012-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery diseases

Interventions

Ezetimibe 10mg/day for one year doubling dose statin for one year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with stable coronary artery disease receiving PCI and IVUS study

Exclusion criteria

Exclusion criteria: 1) prior taking ezetimibe, 2) recent acute coronary syndrome (< 1 year), 3) renal insufficiency (serum creatinine > 2.0 mg / dL), 4) hepatic dysfunction (serum AST or ALT > 3-folds of standard value), 5) cancer, 6) autoimmune diseases, 7) impossibility in decision making 8) consideration as inadequate to participating in the study by attending physician.

Design outcomes

Primary

Measure	Time frame
coronary artery plaque, 1 years after	—

Secondary

Measure	Time frame
clinical events 3 years after lipid profile 1 years after	—

Countries

Japan

Contacts

Public ContactAtsushi Katoh

Kurum University Medical Center Cardiology

katou_atsushi@kurume-u.ac.jp0942-22-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026